Why is OPEC important to the price of crude oil?
High market share gives OPEC bargaining power to price oil above a competitive market. It can sway crude oil prices by increasing or decreasing production.
Healthcare
The latest news in the healthcare sector including biotech and telehealth.
Card loans rule Bank of America’s consumer loan portfolio
Credit card loans account for more than half of Bank of America’s total consumer loan portfolio.
Charlotte’s Web: What to Expect from Q3 Earnings
Charlotte’s Web Holdings (CWEB) (CWBHF) will report third-quarter earnings before the market opens on November 13. Let’s look at analysts’ expectations.
Charlotte’s Web: November Price Target Update
Charlotte’s Web Holdings has fallen 15.44% on the Toronto Stock Exchange. Its stock has dropped 43.58% on the TSE since its Q2 earnings on August 14.
How Are Citadel Advisors Hedging their Portfolio?
Kenneth Cordele Griffin is the CEO of investment management firm Citadel Advisors LLC. He is the hedge fund manager and he founded Citadel in 1990.
US GDP Shatters Expectations, Pessimists Run for Cover
The US GDP increased at an impressive rate of 1.9% for the third quarter. The growth beat the expectations of around 1.6% for the quarter.Consumer Must-know: An overview of Interpublic Group’s businesses
Interpublic Group’s (IPG) companies specialize in consumer advertising, digital marketing, communications planning and media buying, public relations, and specialized communications disciplines.
AbbVie Rapidly Advancing Its 2018 Solid Tumor Portfolio
AbbVie (ABBV) is currently evaluating more than 20 investigational therapies targeting solid tumors. Seventeen of them are in Phase 1 trials.
AbbVie Expects Peak Sales of $7 Billion for Imbruvica
AbbVie (ABBV) has projected Imbruvica’s annual revenues to be $5 billion by 2020. That would be driven by a rapid uptake in the first line chronic lymphocytic leukemia (or CLL) segment.
Ignyta’s Drug Pipeline
Ignyta (RXDX) has completed enrollment for a Phase 1 clinical trial of RXDX-105, an orally bioavailable small molecule tyrosine kinase inhibitor.
Inside Ignyta’s Financial Performance
Ignyta’s (RXDX) R&D (research and development) expenses increased from $16.6 million in 3Q16 to $21.7 million in 3Q17, a 30% rise.
Ignyta and Its Key Risks in 2018
In October 2017, Ignyta (RXDX) raised $150 million by issuing 10 million shares of its common stock.
How Much Cash Is Amazon Holding Abroad?
Apple (AAPL) is said to hold 93.3% of its cash outside the US.
Is 3M’s Biggest-Ever Acquisition Worth the Cost?
3M (MMM) recently spent $6.7 billion to acquire Acelity, a medical-tech company with concentrations in specialized surgical applications and wound care.
Dow Jones and SPY Trade Lower, Retail Data Disappoints
All of the major indexes and ETFs are trading lower today. The Dow Jones Industrial Average has fallen by 44 points or 0.16% at the time of this writing.
Dow Jones Index Falls after Rising for Eight Days
The Dow Jones Industrial Average Index has fallen 0.4% or by 115 points today. The index is trading lower after rising for eight consecutive trading sessions.
These Developments Impacted Abbott Laboratories the Most in Fiscal 2017
Abbott Laboratories posted a strong earnings results on January 24, surpassing Wall Street estimates and posting earnings at the high end of its guidance.
Why Is Lannett Company Soaring Today?
Generic pharmaceutical player Lannett Company (LCI) entered into a distribution agreement with China-based specialty pharmaceutical firm Sinotherapeutics.
Charlotte’s Web Holdings Stock Down after Earnings
Charlotte’s Web Holdings stock (CWBHF)(CWEB) was down 6.6% yesterday after the company reported lower-than-expected Q2 earning results.
Walgreens or CVS Stock: Which Is a Better Value Buy?
Walgreens and CVS Health shares are trading at a low valuation multiple. The stocks have fallen 22.3% and 8.7%, respectively, in 2019.
Walgreens Will Close 200 US Stores
In a regulatory filing on Tuesday, Walgreens Boots Alliance (WBA) announced that it will close 200 stores in the US to focus on store optimization.
Amazon Stock: Does the Recent Slide Indicate a Buy?
Amazon (AMZN) stock has fallen more than 10% since the company reported mixed second-quarter results. The stock fell 3.2% on Monday.
Could CVS Health’s Q2 Results Boost Its Stock?
CVS Health (CVS) is set to announce its second-quarter results on August 7. We expect CVS to sustain its momentum in the quarter, supporting its stock.
How Analysts View Arrowhead Pharmaceuticals
In Q2, Arrowhead Pharmaceuticals reported revenues of $48.15 million—a YoY rise of 7,305.95%—ahead of the consensus estimate by $5.19 million.
Why Is Allakos Soaring Today?
Today, Allakos (ALLK) announced favorable results from its Phase 2 trial evaluating investigational therapy AK002.
Kroger Deal Ignited Charlotte’s Web Holdings Last Week
Charlotte’s Web Holdings’ Kroger deal ignited the stock last week. The stock saw an upwards price action of almost 42%. The stock has risen 86% this year.
NVS or BMY: Who’s Expected to Post Faster Revenue Growth in 2019?
According to the company’s fourth-quarter earnings conference call, Novartis expects to complete the spin-off of its Alcon business in the second quarter of 2019.
FreeStyle Libre Is Multi-Billion Dollar Opportunity for Abbott
In the first quarter, Abbott Laboratories’ (ABT) Diabetes Care franchise reported worldwide sales of $566 million, a YoY rise of 34.4% on a reported basis.
Why Pfizer Stock Continues to Tank after Mylan Deal
Pfizer stock (PFE) has fallen 10% in the past two days on its deal with Mylan (MYL) and its lower earnings guidance.
How Novartis Is Transforming Its Structure in 2019
Since fiscal 2018, Novartis (NVS) has been focused on transforming itself into a new focused medicines company.
How Stryker’s Margins Are Driven by Its CTG Program
Cost transformation for growth (or CTG) is Stryker’s program that focuses on driving leveraged growth by structural cost optimization.
Why Did Intec Pharma Crash on Monday?
On Monday, Intec Pharma (NTEC) closed at $0.55—81.61% lower than the previous close. The company failed the pivotal Phase 3 ACCORDANCE trial.
What to Expect From Bristol-Myers Squibb in Q2
Bristol-Myers Squibb will release its second-quarter earnings on Thursday. The revenues will likely rise 7.16% YoY to $6.11 billion in the second quarter.
A Look at GSK’s Spending and Earnings in Fiscal 2019
In the first-quarter earnings investor presentation, GlaxoSmithKline (GSK) reaffirmed adjusted EPS guidance of a YoY decline of 5%–9% YoY in fiscal 2019.
Comparing Pfizer’s and Merck’s Vaccines Businesses
In the first quarter, Pfizer’s (PFE) vaccine franchise reported revenue of $1.61 billion, a YoY (year-over-year) rise of 10.18%.
Comparing Pfizer’s and Merck’s 2019 Revenue Growth Trajectories
In its first-quarter earnings investor presentation, Pfizer (PFE) reaffirmed its 2019 revenue guidance of $52.0 billion–$54 billion.
What Are Gilead Sciences’ Key Growth Drivers in 2019?
Since the second quarter of 2016, Gilead Sciences has been reporting major YoY revenue declines, mainly due to its lower HCV franchise sales.
BHC’s Salix Segment: Xifaxan Drove Its Revenues in Q1
In the first quarter, Bausch Health Companies (BHC) reported revenues of $445 million for its Salix segment.
Comparing the Revenue Growth Trajectories of PFE and GSK
On its first-quarter earnings conference call, Pfizer (PFE) maintained its 2019 revenue guidance of $52 billion–$54 billion.
Why the US Imposed Sanctions on Iran and Why They Matter
The United States first imposed restrictions on its activities with Iran in 1979, after the seizure of the US embassy in Tehran.
A Look at Cosentyx, Novartis’s Fast-Growing Immunology Drug
In the first quarter, Novartis’s (NVS) Cosentyx reported net sales of $791 million, a YoY (year-over-year) rise of 41% on a constant currency basis.
ANTM or CI: Comparing Their Revenue Growth in 2019
In its fourth-quarter earnings press release, Anthem (ANTM) guided for 2019 operating revenue of $100 billion, a YoY (year-over-year) rise of $8.7 billion.
How Will the Anadarko Acquisition Benefit Chevron?
Chevron (CVX) has agreed to acquire Anadarko (APC) in a cash and equity deal.
Optum Is a Major Differentiator for UnitedHealth Group
In fiscal 2018, UnitedHealth Group’s (UNH) health services business, Optum, reported revenues of $101.3 billion, a YoY rise of 11.07%.
Analysts Raise Their Target Price for Regeneron in March
Wall Street analysts expect a potential upside of 6.79% for Regeneron Pharmaceuticals based on the company’s closing price on March 27.
What’s Hurting CVS and Walgreens Stocks?
Walgreens Boots Alliance stock (WBA) fell 6.4% on March 1 after Baird’s reduction in target price.
AstraZeneca or Eli Lilly: Which Is Controlling Expenses Better?
In its fourth-quarter earnings press release, AstraZeneca (AZN) guided for a low single-digit YoY (year-over-year) rise in core operating expenses in fiscal 2019.
A Look at Spark’s Potential Revenue Contribution to Roche Holdings
Wall Street analysts have projected Spark Therapeutics’ revenues to be $105.64 million, $169.22 million, and $263.76 million for fiscal 2019, fiscal 2020, and fiscal 2021, respectively.
What Are the Key Growth Drivers for GlaxoSmithKline in 2019?
GSK highlighted the prioritization of research and development programs, business development, and new product launches as its key growth drivers in 2018.
What Are the Key Growth Drivers for Eli Lilly in Fiscal 2019?
In its fourth-quarter earnings investor presentation, Eli Lilly (LLY) highlighted its newer products such as Emgality, Verzenio, Olumiant, Lartruvo, Taltz, Basaglar, Jardiance, Trulicity, and Cyramza as its key drivers.
